Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | PRKACA | P17612 | 1/20 | 0.38 |
| ▸ | PRKACG | P22612 | 1/20 | 0.38 |
| ▸ | PRKACB | P22694 | 1/20 | 0.38 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.37 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.37 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.37 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.37 |
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CRHBP | P24387 | 1/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20610137 | 0.80 | ALDH1A1 (0.41) | ALDH1A1LMNATDP1KMT2APRKACA | |
| SCHEMBL20401810 | 0.76 | ALDH1A1 (0.49) | GAAALDH1A1TSHRCYP3A4RECQL | |
| SCHEMBL14183096 | 0.75 | GAA (0.50) | GAAALDH1A1TSHRCYP3A4RECQL | |
| SCHEMBL867235 | 0.74 | ALDH1A1 (0.50) | GAAALDH1A1TSHRCYP3A4RECQL | |
| SCHEMBL27564899 | 0.74 | TDP1 (0.46) | GAAALDH1A1TSHRCYP3A4LMNA | |
| SCHEMBL30912584 | 0.74 | ALDH1A1 (0.44) | GAAALDH1A1TSHRCYP3A4LMNA | |
| SCHEMBL2756376 | 0.73 | ALDH1A1 (0.46) | GAAALDH1A1TSHRCYP3A4RECQL | |
| SCHEMBL5058414 | 0.72 | KMT2A (0.40) | GAAALDH1A1TSHRCYP3A4LMNA | |
| SCHEMBL5545595 | 0.72 | MAPT (0.44) | PRKACAPRKACGPRKACBMAPT | |
| SCHEMBL27491169 | 0.71 | DRD2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270912-A1 | Substituted Indolealkanoic Acids | JONES MICHAEL LEE (US) | 2012-10-25 | — | — | US | disclosed |
| US-8163932-B2 | Substituted indolealkanoic acids | ALINEA PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20120065203-A1 | Methods of Reducing Serum Glucose and Triglyceride Levels and for Inhibiting Angiogenesis Using Substituted Indolealkanoic Acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2012-03-15 | — | — | US | disclosed |
| US-20100324105-A1 | Methods of Reducing Serum Glucose and Triglyceride Levels and for Inhibiting Angiogenesis Using Substituted Indolealkanoic Acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC | 2010-12-23 | — | — | US | disclosed |
| US-20100324039-A1 | Substituted Indolealkanoic Acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC | 2010-12-23 | — | — | US | disclosed |
| US-20100137301-A1 | Substituted Indolealkanoic Acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC | 2010-06-03 | — | — | US | disclosed |
| US-7659269-B2 | Substituted indolealkanoic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2010-02-09 | — | — | US | disclosed |
| US-20080214540-A1 | 3-[(phenyl or benzothiazol-2-yl)methyl]indole-N-acetic acids and esters; analgesics; aldose reductase inhibitors; diabetes complications including cataracts, retinopathy, nephropathy, and neuropathy; side effect reduction | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC | 2008-09-04 | — | — | US | disclosed |
| US-7304079-B2 | Preparing 3-benzothiazolylalkyl-1-indolylacetic acids and esters by cyclizing a 3-(anilinothiocarbonylalkyl)-1-indolylacetic ester with potassium ferricyanide or sodium hydride, optionally deprotecting the acid group; aldose reductase inhibitors for diabetic complications; side effect reduction | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2007-12-04 | — | — | US | disclosed |
| US-20070093530-A1 | SUBSTITUTED INDOLEALKANOIC ACIDS | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC | 2007-04-26 | — | — | US | disclosed |
| US-20010041722-A1 | Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor | ALINEA PHARMACEUTICALS, INC. | 2001-11-15 | — | — | US | disclosed |
| EP-1135124-A2 | ANTIHYPERTRIGLYCERIDEMIC, ANTIHYPERGLYCEMIC, ANTI-ANGIOGENIC AND WOUND HEALING SUBSTITUDED INDOLEALKANOIC ACIDS | The Institutes for Pharmaceutical Discovery, Inc. (US) | 2001-09-26 | — | — | EP | disclosed |
| WO-2001064205-A2 | COMPOSITIONS CONTAINING A SUBSTITUTED INDOLEALKANOIC ACID AND AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2001-09-07 | — | — | WO | disclosed |
| US-20010016661-A1 | Substituted indolealkanoic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY | 2001-08-23 | — | — | US | disclosed |
| WO-2001051489-A2 | METHODS FOR LOWERING URIC ACID LEVELS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2001-07-19 | — | — | WO | disclosed |
| CN-1296485-A | Substituted indolealkanoic acids | INST FOR PHARM DISCOVERY INC (US) | 2001-05-23 | — | — | CN | disclosed |
| US-6214991-B1 | 3-(4,5,7-TRIFLUOROBENZOTHIAZOL-2-YL)METHYL-INDOLE-N-ACETIC ACID, ETHYL ESTER FOR EXAMPLE; TREATING COMPLICATIONS OF DIABETES MELLITUS, SUCH AS CATARACTS, RETINOPATHY, NEPHROPATHY, AND NEUROPATHY | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, INC. | 2001-04-10 | — | — | US | disclosed |
| EP-1066283-A2 | SUBSTITUTED INDOLEALKANOIC ACIDS | The Institutes for Pharmaceutical Discovery, Inc. (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-2000032180-A2 | ANTIHYPERTRIGLYCERIDEMIC, ANTIHYPERGLYCEMIC, ANTI-ANGIOGENIC AND WOUND HEALING SUBSTITUTED INDOLEALKANOIC ACIDS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, INC. (US) | 2000-06-08 | — | — | WO | disclosed |
| WO-1999050268-A2 | SUBSTITUTED INDOLEALKANOIC ACIDS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, INC. (US) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010016661-A1 | Substituted indolealkanoic acids | GPR119, AANAT, AADAT | GAA 1223/4885ALDH1A1 338/4885TSHR 1010/4885 |
| US-20120065203-A1 | Methods of Reducing Serum Glucose and Triglyceride Levels and for Inhibiting Angiogenesis Using Substituted Indolealkanoic Acids | LIPG, PNLIP, LIPA | GAA 663/4885ALDH1A1 513/4885TSHR 967/4885 |
| US-20100324039-A1 | Substituted Indolealkanoic Acids | GPR119, AANAT, AADAT | GAA 1223/4885ALDH1A1 338/4885TSHR 1010/4885 |
| US-20100324105-A1 | Methods of Reducing Serum Glucose and Triglyceride Levels and for Inhibiting Angiogenesis Using Substituted Indolealkanoic Acids | LIPG, PNLIP, LIPA | GAA 663/4885ALDH1A1 513/4885TSHR 967/4885 |
| US-20010041722-A1 | Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor | AGT, LIPG, ACE | GAA 179/4885ALDH1A1 288/4885TSHR 1364/4885 |
| US-20070093530-A1 | SUBSTITUTED INDOLEALKANOIC ACIDS | GPR119, AANAT, AADAT | GAA 1223/4885ALDH1A1 338/4885TSHR 1010/4885 |
| US-20100137301-A1 | Substituted Indolealkanoic Acids | GPR119, AANAT, AADAT | GAA 1223/4885ALDH1A1 338/4885TSHR 1010/4885 |
| US-20120270912-A1 | Substituted Indolealkanoic Acids | GPR119, AANAT, AADAT | GAA 1223/4885ALDH1A1 338/4885TSHR 1010/4885 |
| US-20080214540-A1 | 3-[(phenyl or benzothiazol-2-yl)methyl]indole-N-acetic acids and esters; analgesics; aldose reductase inhibitors; diabetes complications including cataracts, retinopathy, nephropathy, and neuropathy; side effect reduction | AKR1C3, AKR1C2, AKR1B1 | GAA 1520/4885ALDH1A1 31/4885TSHR 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.